Contact

Myralune Home About Services Evidence Review Risk & Safety Research Roadmap Contact Evidence, uncertainty, and risk Ibogaine Science: The Evidence Base Reviewed Ibogaine draws serious interest for addiction treatment, especially opioid use disorder, while carrying substantial safety risks and an evidence base that remains incomplete. This independent resource separates promising signals from established clinical evidence and keeps patient safety in view. Starting with scope What ibogaine is—and what a review can responsibly say Ibogaine is an indole alkaloid derived from the root bark of the Tabernanthe iboga plant, native to Central West Africa. For centuries, indigenous Bwiti spiritual traditions in Gabon have used iboga in rites of passage and healing ceremonies. Its psychoactive properties entered Western scientific literature in the late 19th century. Today, ibogaine science concerns a psychoactive compound being explored for drug addiction, opioid use disorder, other substance use disorders, and some mental health conditions. A broad search of ibogaine scholarship shows sustained interest, but interest is not the same as a settled evidence base. Its place in psychedelic medicine is therefore unusual: reports of rapid change are compelling, yet the clinical research needed to establish efficacy, dosing, contraindications, and long-term abstinence is limited. The U.S. Drug Enforcement Administration’s scheduling framework helps explain why formal research and routine access have diverged. The central question is not whether ibogaine has effects. It does. The question is which effects translate into safe, reproducible treatment under rigorous clinical conditions. Traditional origin and modern research should be considered together, without treating either as proof of clinical efficacy. Mechanisms, not conclusions Why one compound can produce so many effects Ibogaine and its primary metabolite, noribogaine, affect multiple neurotransmitter systems, including o

Contact

Keeping the conversation clear